References
- BonfocoEKraincDAnkarcronaMNicoteraPLiptonSAApoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell culturesProc Natl Acad Sci U S A199592716271667638161
- BormannJMemantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channelsEur J Pharmacol19891665915922553441
- RainerMWuschitzAJagschCErbCChirikdjianJJMuckeHAMemantine in moderate to severe Alzheimer’s disease: an observational post-marketing studyJ Neural Transm201121181255125921461744
- BermanFWMurrayTFCharacterization of [3H]MK-801 binding to N-methyl-D-aspartate receptors in cultured rat cerebellar granule neurons and involvement in glutamate-mediated toxicityJ Biochem Toxicol1996112172269110243
- MoriyoshiKMasuMIshiiTShigemotoRMizunoNNakanishiSMolecular cloning and characterization of the rat NMDA receptorNature199135431371834949
- IshiiTMoriyoshiKSugiharaHMolecular characterization of the family of the N-methyl-D-aspartate receptor subunitsJ Biol Chem1993268283628438428958
- NorthWGGaoGMemoliVAPangRHLynchLBreast cancer expresses functional NMDA receptorsBreast Cancer Res Treat201012230731419784770
- NorthWGGaoGJensenAMemoliVDuJNMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatmentClin Pharmacol20102314022291485
- TuzinEZhouLBaehringJMBannikhSResenfeldMRDalmauJEvidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratomaActa Neuropathol200911873774319680671
- DalmauJGleichmanAJHughesEGAnti-NMDA encephalitis: case series and analysis of the effects of antibodiesLancet Neurol200871091109818851928
- WillAAkalinMParaneoplastic limbic encephalitis with NMDA receptor (NR1) antibodies in breast cancerNeurology201278S08.007
- TachibanaNShirakawaTIshiiKExpression of various glutamate receptors including N-methyl-D-aspartate receptor (NMDAR) in ovarian teratoma removed from a young woman with anti-NMDAR encephalitisIntern Med2010492167217320930449
- TachibanaNIkedaSLocalization of NMDAR-related epitopes in ovarian teratoma: comparison between patients and controlsRinsho Shinkeigaku20125298298423196491
- DuringMJSymesCWLawlorPAAn oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsyScience20002871453146010688787
- KawaiYHirakawaTSugisawaAMotomuraIAcute and sub-acute toxicity studies of ifenprodilOyo Yakuri Pharmacometrics197510785
- ShalabyIAChenardBLProchniakMAButlerTWNeuroprotective effects of the N-methyl-D-aspartate receptor antagonists ifenprodil and SL-82.0715 on hippocampal cells in cultureJ Pharmacol Exp Ther19922609259321346650
- GrahamDDarlesGLangerSZThe neuroprotective properties of ifenprodil, a novel NMDA receptor antagonist, in neuronal cell culture toxicity studiesEur J Pharmacol19922263733761356814
- MishraVVermaRSinghNRaghubirRThe neuroprotective effects of NMDAR antagonist, ifenprodil and ASIC1a inhibitor, flurbiprofen on post-ischemic cerebral injuryBrain Res2011138915216021396924
- ZhangWShiCXGuXPMaZLZhuWAntinociception and decreased the expression of NR2B subunits in the dorsal horn after chronic dorsal root ganglia compression in ratsAnesth Analg20091081015102019224818
- ReynoldsIJMillerRJIfenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyaminesMol Pharmacol1989367587652555674
- WilliamsKIfenprodil discriminates subtypes of N-methyl-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptorsMol Pharmacol1993448518597901753
- GallagherMJHuangHPritchettDBLynchDRInteractions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptorJ Biol Chem1996271960396118621635
- BernardiMBertoliniASzczawinskaKGenedaniSBlockage of polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine in miceEur J Pharmacol199629851558867919
- ChizhBAHeadleyPMTzschentkeTMNMDA receptor antagonists as analgesics focus on the NR2B subtypeTrends Pharmacol Sci20012263664211730974
- Patent Abstracts of Japan Vol 10 no.377 (c-392) 16 December, 1986; and JP-A-61 72820(Grelan Pharmaceutical Co, Ltd), 4 December, 1986.